Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 2CNS 1

Conditions

Pheochromocytoma 2Paraganglioma 1

Interventions

3-Iodobenzylguanidine 14Temozolomide 6lutetium Lu 177 dotatate 5gallium Ga 68 dotatate 4anlotinib 4Specimen Handling 4Everolimus 4Radiotherapy 3Phenoxybenzamine 3Magnetic Resonance Spectroscopy 3Doxorubicin 36-fluorodopamine 33-fluorobenzylguanidine 3pegfilgrastim 2olaparib 2fluorodopa F 18 2cabozantinib 2belzutifan 2Nivolumab 2Ifosfamide 2Granulocyte Colony-Stimulating Factor 2Fluorodeoxyglucose F18 2Filgrastim 2Doxazosin 2Dexmedetomidine 2Capecitabine 2Biopsy 2Axitinib 2Adrenalectomy 2177Lu-octreotide, DOTA(0)-Tyr(3)- 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Pheochromocytoma × Doxazosin × Endocrine × Clear all
NCT01379898 2024-09-19

PRESCRIPT

University Medical Center Groningen

Phase 4 Completed
134 enrolled
Endocrine

Pheochromocytoma

NCT03176693 2023-11-20

Preoperative Alpha Blockade for Pheochromocytoma

University of California, Los Angeles

Phase 3 Completed
39 enrolled 8 charts
CNSEndocrine

Paraganglioma, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡